## Scott Kinlay

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1287099/publications.pdf Version: 2024-02-01

		535685	511568
33	1,722 citations	17	30
papers	citations	h-index	g-index
33	33	33	2754
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Premature Discontinuation of Dual Antiplatelet Therapy After Coronary Stenting in Veterans: Characteristics and Longâ€Term Outcomes. Journal of the American Heart Association, 2021, 10, e018481.	1.6	9
2	Reproducibility and validity of a novel invasive method of assessing peripheral microvascular vasomotor function. PLoS ONE, 2019, 14, e0211152.	1.1	0
3	Reply to: â€~Post-exercise criteria to diagnose lower extremity peripheral artery disease: Which one should I use in my practice?' by Stivalet et al Vascular Medicine, 2019, 24, 78-78.	0.8	0
4	Prognosis of patients with secondary mitral regurgitation and reduced ejection fraction. Open Heart, 2018, 5, e000745.	0.9	13
5	Comparison of different exercise ankle pressure indices in the diagnosis of peripheral artery disease. Vascular Medicine, 2018, 23, 541-548.	0.8	19
6	The 2016 AHA/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease: An interview with SVM members of the writing committee. Vascular Medicine, 2017, 22, 170-173.	0.8	5
7	Claudication. JACC: Cardiovascular Interventions, 2017, 10, 725-727.	1.1	4
8	Longâ€ŧerm outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting. Catheterization and Cardiovascular Interventions, 2017, 89, 1176-1184.	0.7	5
9	Management of Critical Limb Ischemia. Circulation: Cardiovascular Interventions, 2016, 9, e001946.	1.4	114
10	Does This Study Make My Aorta Look Fat?. Circulation, 2015, 132, 1600-1601.	1.6	2
11	Protocol for Exercise Hemodynamic Assessment: Performing an Invasive Cardiopulmonary Exercise Test in Clinical Practice. Pulmonary Circulation, 2015, 5, 610-618.	0.8	68
12	Outcomes with prolonged clopidogrel therapy after coronary stenting in patients with chronic kidney disease. Heart, 2015, 101, 1569-1576.	1.2	27
13	Endovascular Intervention for Peripheral Artery Disease. Circulation Research, 2015, 116, 1599-1613.	2.0	200
14	Long-Term Outcomes in Patients With Diabetes Mellitus Related to Prolonging Clopidogrel More Than 12 Months AfterÂCoronary Stenting. Journal of the American College of Cardiology, 2015, 66, 1091-1101.	1.2	28
15	Outcomes for Clinical Studies Assessing Drug and Revascularization Therapies for Claudication and Critical Limb Ischemia in Peripheral Artery Disease. Circulation, 2013, 127, 1241-1250.	1.6	27
16	The Management of Carotid Stenoses in the Elderly. Current Cardiovascular Risk Reports, 2012, 6, 425-430.	0.8	0
17	Role of C-Reactive Protein When Prescribing a Statin. Current Atherosclerosis Reports, 2012, 14, 26-32.	2.0	2
18	Longâ€term risk of clinical events from stenting side branches of coronary bifurcation lesions with drugâ€eluting and bareâ€metal stents: An observational metaâ€analysis. Catheterization and Cardiovascular Interventions, 2011, 77, 202-212.	0.7	19

SCOTT KINLAY

#	Article	IF	CITATIONS
19	Percutaneous revascularization of long femoral artery lesions for claudication. Catheterization and Cardiovascular Interventions, 2011, 77, 1055-1062.	0.7	26
20	Changes in Stroke Epidemiology, Prevention, and Treatment. Circulation, 2011, 124, e494-6.	1.6	44
21	Subclavian stenosis causing angina after coronary artery bypass grafting. Medical Journal of Australia, 2009, 190, 331-332.	0.8	3
22	Low-Density Lipoprotein-Dependent and -Independent Effects of Cholesterol-Lowering Therapies on C-Reactive Protein. Journal of the American College of Cardiology, 2007, 49, 2003-2009.	1.2	161
23	Potential vascular benefits of statins. American Journal of Medicine, 2005, 118, 62-67.	0.6	22
24	Effects of statins on inflammation in patients with acute and chronic coronary syndromes. American Journal of Cardiology, 2003, 91, 9-13.	0.7	56
25	Coronary Flow Velocity and Disturbed Flow Predict Adverse Clinical Outcome After Coronary Angioplasty. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1334-1340.	1.1	16
26	Endothelium-Derived Nitric Oxide Regulates Arterial Elasticity in Human Arteries In Vivo. Hypertension, 2001, 38, 1049-1053.	1.3	346
27	Role of Endothelin-1 in the Active Constriction of Human Atherosclerotic Coronary Arteries. Circulation, 2001, 104, 1114-1118.	1.6	148
28	Relationship of Clinical Presentation and Calcification of Culprit Coronary Artery Stenoses. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1618-1622.	1.1	200
29	Pathophysiology of atherosclerosis: Development, regression, restenosis. Current Atherosclerosis Reports, 2000, 2, 251-258.	2.0	7
30	Treating ambulatory ischemia in coronary disease by manipulating the cell biology of atherosclerosis. Current Atherosclerosis Reports, 2000, 2, 321-326.	2.0	4
31	Atherogenic Lipids and Endothelial Dysfunction: Mechanisms in the Genesis of Ischemic Syndromes. Annual Review of Medicine, 2000, 51, 149-167.	5.0	58
32	Effect of lipid-lowering therapy on vasomotion and endothelial function. Current Cardiology Reports, 1999, 1, 238-243.	1.3	14
33	Atherogenic Lipids, Vascular Dysfunction, and Clinical Signs of Ischemic Heart Disease. Circulation, 1997, 95, 5-7.	1.6	75